Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
<sup>177</sup>Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). <sup>177</sup>Lu-DOTATOC is a pate...
Main Authors: | Myrna Luna-Gutiérrez, Rodrigo Hernández-Ramírez, Airam Soto-Abundiz, Osvaldo García-Pérez, Alejandra Ancira-Cortez, Sergio López-Buenrostro, Brenda Gibbens-Bandala, Irma Soldevilla-Gallardo, Nancy Lara-Almazán, Melissa Rojas-Pérez, Blanca Ocampo-García, Erika Azorín-Vega, Clara Santos-Cuevas, Guillermina Ferro-Flores |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/7/1988 |
Similar Items
-
<sup>90</sup>Y/<sup>177</sup>Lu-DOTATOC: From Preclinical Studies to Application in Humans
by: Licia Uccelli, et al.
Published: (2021-09-01) -
Toxicity Assessment of [<sup>177</sup>Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
by: Tania Hernández-Jiménez, et al.
Published: (2022-11-01) -
<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01) -
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&T
by: Philipp E. Hartrampf, et al.
Published: (2022-01-01) -
Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-12-01)